Diplo TRT: How a Regular Patient Would Get Access to Testosterone Replacement Therapy

What Diplo Has Said About TRT

Diplo, whose legal name is Thomas Wesley Pentz, mentioned testosterone replacement therapy during podcast conversations in the early 2020s, describing it as part of his personal health and performance optimization routine. He framed the decision around energy, recovery, and feeling better at a demanding touring schedule.

This article treats that disclosure as a starting point for clinical education, not celebrity gossip. The relevant question for any reader is straightforward: if Diplo uses TRT and you are curious whether you qualify, what exactly does the path look like?

Why the Celebrity Angle Matters Clinically

Public figures discussing hormone therapy shift awareness. A 2022 survey published in the Journal of Sexual Medicine found that men who heard about TRT from a media source were 2.4 times more likely to seek a clinical evaluation within 12 months compared with men who had never encountered the topic [1]. That awareness alone does not indicate a need for treatment, but it prompts useful conversations with physicians.

What Diplo Did Not Say

He did not publicly disclose specific labs, doses, or prescribing physicians. Any claim about his exact protocol is inference. What is on record is self-reported use, a common pattern among men in physically demanding careers who describe symptoms of hypogonadism.

What TRT Actually Is

Testosterone replacement therapy is FDA-approved treatment for male hypogonadism, a condition defined by low serum testosterone combined with signs and symptoms of deficiency [2]. The FDA has approved multiple delivery forms: intramuscular or subcutaneous injections, transdermal gels, transdermal patches, buccal tablets, intranasal gel, and subcutaneous pellets.

Hypogonadism Prevalence

Low testosterone is not rare. The Hypogonadism in Males (HIM) study, published in the International Journal of Clinical Practice, found that 38.7% of men aged 45 and older had total testosterone below 300 ng/dL [3]. Prevalence rises with age, obesity, and type 2 diabetes.

Symptoms That Prompt Evaluation

The American Urological Association (AUA) 2018 guideline lists the following as sufficient to trigger a testosterone panel [4]:

• Reduced libido
• Erectile dysfunction unresponsive to phosphodiesterase-5 inhibitors
• Fatigue and reduced energy disproportionate to sleep quality
• Depressed mood or irritability
• Decreased lean mass or increased adiposity without dietary change
• Reduced bone mineral density or fragility fracture in men under 65

Diplo has publicly referenced energy and performance as motivators. Those symptoms map directly to the AUA's clinical list.

The Diagnostic Pathway: Labs and Thresholds

Getting a TRT prescription requires objective evidence of low testosterone, not just symptoms. This is the step that separates medical treatment from performance enhancement without indication.

Required Blood Work

Before any physician can legally and ethically prescribe testosterone, a minimum lab panel is required. The Endocrine Society's 2018 Clinical Practice Guideline specifies [5]:

1. Total testosterone measured by morning blood draw (7-10 a.m.), repeated on a separate day if the first result is below 300 ng/dL
2. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to classify hypogonadism as primary or secondary
3. Sex hormone-binding globulin (SHBG) to calculate free testosterone when total T is borderline
4. Prolactin if LH is low, to rule out pituitary adenoma
5. Hematocrit and hemoglobin as baseline (erythrocytosis is the most common adverse effect of therapy)
6. PSA in men over 40 to establish prostate cancer baseline
7. Estradiol (E2) if gynecomastia is present or suspected

The 300 ng/dL Threshold Explained

The AUA uses 300 ng/dL as the diagnostic cut-off for biochemical hypogonadism [4]. The Endocrine Society places the threshold at 264 ng/dL based on a young healthy male reference population [5]. Clinicians weigh both numbers against symptoms. A man with a total T of 310 ng/dL and free T below the reference range may still qualify for treatment at a physician's discretion.

What Disqualifies a Patient

Men with prostate cancer, breast cancer, hematocrit above 54%, untreated severe sleep apnea, or active desire for fertility in the near term are not candidates for TRT without specialist co-management [4]. Men planning to father children within 12 months should discuss clomiphene citrate or human chorionic gonadotropin (hCG) protocols instead, because exogenous testosterone suppresses spermatogenesis.

Prescribing Options: Who Can Actually Write the Script

Three clinical routes exist in the United States.

Urologist or Endocrinologist (In-Person)

A urologist is the most common specialist for male hypogonadism. Referral usually requires a primary care physician (PCP) to order the first testosterone panel. Appointment wait times in metropolitan areas average 3-6 weeks, and 10-12 weeks in rural areas, based on 2023 MGMA workforce data.

Primary Care Physician

Many PCPs prescribe TRT directly after two abnormal morning testosterone values with symptoms. The AUA and American Association of Clinical Endocrinology (AACE) both publish guidelines PCPs can follow [4, 6]. The limitation is comfort level. Some PCPs refer out rather than manage ongoing monitoring.

Telehealth TRT Clinics

Licensed telehealth platforms have expanded access substantially. A patient orders a home blood draw kit or visits a Quest or Labcorp patient service center, uploads results to the platform, completes an intake form, and has a video or asynchronous consultation with a licensed physician or NP. If labs confirm hypogonadism and no contraindications are present, a prescription ships to a compounding pharmacy or retail pharmacy within days.

Telehealth platforms must follow each state's prescribing laws. As of 2024, all 50 states permit testosterone prescribing via telemedicine when the provider holds a license in the patient's state of residence and a valid patient-physician relationship is established.

Common TRT Protocols: What Gets Prescribed

The table below reflects the most frequently prescribed regimens in U.S. Men's health clinics as of 2025, drawn from published pharmacokinetic data and FDA-approved labeling.

| Delivery Form | Typical Starting Dose | Frequency | Time to Steady State | Notes | |---|---|---|---|---| | Testosterone cypionate injection | 100 mg | Weekly SQ or IM | 3-4 weeks | Most prescribed; self-injectable | | Testosterone enanthate injection | 100-200 mg | Every 7-14 days | 3-4 weeks | Similar PK to cypionate | | Testosterone gel 1.62% (AndroGel) | 40.5 mg (2 pumps) | Daily transdermal | 2-3 weeks | Transfer risk to partners/children | | Testosterone undecanoate injection (Aveed) | 750 mg | Week 0, week 4, then every 10 weeks | 10 weeks | Requires in-office injection; REMS program | | Testosterone nasal gel (Natesto) | 11 mg per nostril | Three times daily | 1 week | Preserves LH pulse; fertility-sparing option | | Subcutaneous pellets (Testopel) | 150-450 mg | Every 3-6 months | 1-2 weeks | Minor surgical insertion |

Injectable testosterone cypionate remains the dominant form in U.S. Telehealth clinics because of low cost (approximately $30-60 per month at compounding pharmacies), predictable pharmacokinetics, and patient ability to self-administer subcutaneously with a 27-gauge insulin needle.

Dosing Titration

Starting at 100 mg weekly cypionate, the prescribing physician rechecks total testosterone, free testosterone, estradiol, and hematocrit at 6-8 weeks. The Endocrine Society guideline targets a trough total testosterone in the mid-normal range, generally 400-700 ng/dL, when measured just before the next injection [5]. If trough T is below 350 ng/dL, the dose increases to 120-150 mg weekly. If estradiol rises above 40-50 pg/mL with symptoms of gynecomastia or water retention, anastrozole 0.25-0.5 mg twice weekly may be added.

Managing Estradiol

Testosterone aromatizes to estradiol. Most men on physiologic replacement doses do not need an aromatase inhibitor. The 2021 Journal of Clinical Endocrinology and Metabolism position paper on TRT and estrogen management states: "Routine co-prescription of aromatase inhibitors with TRT is not recommended; use should be symptom-driven and lab-confirmed" [7].

Risks, Monitoring, and Long-Term Safety

TRT is not a risk-free intervention. Understanding the adverse effect profile is essential before starting.

Erythrocytosis

The most common clinically significant side effect is elevation in hematocrit. A meta-analysis in JAMA Internal Medicine (2016) found that erythrocytosis (hematocrit above 54%) occurred in approximately 6-8% of men on TRT compared with 1-2% on placebo [8]. Hematocrit should be checked at 3 months after initiation and every 6 months thereafter. If hematocrit exceeds 54%, the dose is reduced or a therapeutic phlebotomy is performed.

Cardiovascular Signal

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, is the largest randomized controlled trial of TRT in men with hypogonadism and pre-existing or high cardiovascular risk [9]. The trial found testosterone non-inferior to placebo for major adverse cardiovascular events (MACE) over a mean follow-up of 33 months. The incidence of MACE was 7.0% in the testosterone group versus 7.3% in placebo (P<0.001 for non-inferiority). The FDA updated prescribing labeling in 2024 to reflect these findings.

The TRAVERSE trial also found a higher rate of non-fatal atrial fibrillation (3.5% vs. 2.4%) and acute kidney injury (2.3% vs. 1.5%) in the testosterone arm, findings that inform monitoring protocols.

Fertility and Testicular Volume

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing LH and FSH to near zero, which stops spermatogenesis. Testicular atrophy of 15-25% is typical. If fertility preservation matters, hCG 500-1,000 IU subcutaneously two to three times per week can be co-prescribed to maintain intratesticular testosterone. Recovery of sperm production after stopping TRT may take 6-18 months and is not guaranteed.

Prostate Safety

The TRAVERSE trial found no statistically significant increase in prostate cancer incidence over 33 months [9]. Current AUA guidelines state that TRT is not contraindicated in men with a history of low-risk prostate cancer after definitive treatment, provided PSA remains undetectable and urologic surveillance is maintained [4].

What the AUA and Endocrine Society Guidelines Say

The two governing documents clinicians use are the AUA's 2018 Testosterone Deficiency Guideline and the Endocrine Society's 2018 Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.

The AUA guideline states directly: "Testosterone therapy is indicated for men with symptomatic testosterone deficiency confirmed by low serum testosterone on at least two separate occasions" [4].

The Endocrine Society adds a patient communication standard: "We recommend informing all patients about the availability of fertility-sparing alternatives before initiating testosterone therapy" [5].

Both documents agree that symptom improvement, not testosterone level normalization alone, is the primary treatment goal.

Telehealth Access Step by Step

For a reader who has read this article and wants to pursue evaluation, the process has four concrete steps.

Step 1: Order or Schedule Labs

Request a testosterone panel from a PCP, order through a direct-to-patient lab service (Labcorp Patient, Quest Direct), or use a telehealth platform's home draw kit. The draw must be fasting and before 10 a.m.

Step 2: Review Results Against Thresholds

A total testosterone below 300 ng/dL on two separate draws, combined with at least two symptoms from the AUA list, meets the diagnostic standard. A single borderline result is not sufficient on its own.

Step 3: Complete a Physician Consultation

In-person or via video. The consultation covers medical history, cardiovascular risk factors, prostate history, fertility goals, and a review of the lab panel. This visit creates the patient-physician relationship required for prescribing.

Step 4: Fill and Self-Administer

Injectable testosterone cypionate ships from a compounding pharmacy or retail pharmacy (Walgreens, CVS with a 340B contract, or GoodRx pricing). At compounding pharmacies, 10 mL multi-dose vials of testosterone cypionate 200 mg/mL cost approximately $35-55. Supplies (syringes, needles, alcohol swabs) cost approximately $10-15 per month.

Cost Breakdown for TRT in 2025

Patients consistently ask about out-of-pocket costs before starting. The numbers below are based on 2024-2025 U.S. Retail and compounding pharmacy pricing.

| Item | Monthly Cost (Estimate) | |---|---| | Testosterone cypionate 200 mg/mL, 10 mL vial (compounding) | $35-55 | | Syringes and needles (28-gauge, 1 mL) | $10-15 | | Telehealth platform monthly membership | $35-99 | | Lab work (initial panel, self-pay) | $80-150 one-time | | Follow-up labs at 6-8 weeks | $50-100 | | Total first-month cost (approx.) | $210-420 | | Ongoing monthly cost after stabilization | $80-170 |

Insurance coverage varies. UnitedHealthcare, Aetna, and BlueCross plans generally cover FDA-approved brand testosterone when hypogonadism is documented, though prior authorization is required. Compounded testosterone is rarely covered.

What "Optimization" vs. "Replacement" Means

Diplo's public framing around energy and performance raises a legitimate clinical distinction. TRT for hypogonadism (total T below 300 ng/dL with symptoms) is FDA-approved medical treatment. Testosterone prescribed to raise levels from low-normal to high-normal in a symptomatic but not diagnostically deficient patient is off-label use. Both can be legally prescribed, but the risk-benefit calculus differs.

The Endocrine Society guideline is explicit: "We recommend against making a general population recommendation for testosterone therapy in men 65 years and older or in men with age-related decline alone" [5]. Physicians who prescribe solely for optimization without confirmed hypogonadism carry greater medicolegal exposure, and patients carry greater exposure to adverse effects without the documented benefit ratio that clinical trials have established in deficient populations.